NEW YORK CITY, NY / ACCESS Newswire / August 3, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Biohaven Ltd. ("Biohaven" or the "Company") (NYSE:BHVN) and certain officers. The class action, filed in the United States District Court for the District of Connecticut, and docketed under 25-cv-01120, is on […]
NEW YORK CITY, NY / ACCESS Newswire / August 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of The Bancorp, Inc. ("Bancorp" or "the Company") (NASDAQ:TBBK). Investors who purchased Bancorp securities prior to January 25, 2024, and continue to hold to the present, are encouraged to obtain
NEW YORK, NY / ACCESS Newswire / August 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Manhattan Associates, Inc. ("Manhattan Associates" or "the Company") (NASDAQ:MANH). Investors who purchased Manhattan Associates securities prior to October 22, 2024, and continue to hold to the present, are encouraged to
NEW YORK, NY / ACCESS Newswire / August 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. ("Edgewise" or the "Company") (NASDAQ:EWTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Edgewise and certain of its officers and/or directors
Venture Medical, LCC is sharing our position on the CY2026 Medicare Physician Fee Schedule and our future recommendations. MISSOULA, MT / ACCESS Newswire / August 3, 2025 / The proposed changes to skin substitute reimbursement and coverage in the CY2026 Medicare Physician Fee Schedule (PFS) and Future Effective Local Coverage Determinations (LCDs) are unprecedented and
NEW YORK CITY, NY / ACCESS Newswire / August 3, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Sable Offshore Corp. ("Sable" or the "Company") (NYSE:SOC).�� Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are
NEW YORK CITY, NY / ACCESS Newswire / August 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Molina Healthcare, Inc. ("Molina" or the "Company") (NYSE:MOH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Molina and certain of its officers and/or
NEW YORK CITY, NY / ACCESS Newswire / August 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Anika Therapeutics, Inc. ("Anika" or the "Company") (NASDAQ:ANIK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Anika and certain of its officers and/or
NEW YORK CITY, NY / ACCESS Newswire / August 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE:NVO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Novo Nordisk and certain of its
NEW YORK, NY / ACCESS Newswire / August 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or the "Company") (NASDAQ:DYN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Dyne and certain of its officers and/or directors